Neuronetics, Inc. (STIM) stock
Close on Nov 13, 2026Market cap $105.91MP/E –Yield –
Neuronetics, Inc. grew revenue 23.0% to $159.76M over the twelve months to Sep 30, 2026. Free cash flow was -$9.61M. At the latest close the market valued the company at $105.91M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $105.91M
- P/E ratio
- –
- Price to sales
- 0.66
- Price to book
- 5.66
- Dividend yield
- –
- Free cash flow yield
- -9.07%
Fundamentals
- Revenue
- $159.76M
- Net income
- -$23.08M
- EPS, diluted
- -$0.33
- Free cash flow
- -$9.61M
- Book value per share
- $0.24
- Diluted shares
- 77M
Trading
- Next earnings
- Mar 16, 2027 (estimated, before the open)
- Previous close
- $1.43
- Open
- $1.21
- Day's range
- $1.20 – $1.44
- Volume
- 16,259,540
- Average volume (20 days)
- 2,845,836
- Beta (5 years)
- 1.58
- 52-week range
- $0.80 – $3.44
- RSI (14 days)
- 31.6
- Volatility (1 year)
- 119.7%
- Relative volume
- 8.20×
- WACC
- 12.4%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | STIM | S&P 500 | Difference | STIM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.2% | -3.0% | −27.1 pts | ||
| 3 months | -54.1% | -2.8% | −51.3 pts | ||
| Year to date | +0.7% | +11.5% | −10.8 pts | ||
| 1 year | -31.9% | +13.5% | −45.3 pts | ||
| 3 years | +11.2% | +77.7% | −66.5 pts | +3.6% | +21.1% |
| 5 years | -72.9% | +72.6% | −145.5 pts | -23.0% | +11.5% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Neuronetics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Results
- Results
- Results
- Results
About Neuronetics
Surgical & Medical Instruments & Apparatus
Neuronetics, Inc. is a medical technology company specializing in neurohealth solutions and transcranial magnetic stimulation (TMS) therapy. Its flagship product is the NeuroStar Advanced Therapy System, an FDA-cleared, non-invasive office-based platform designed to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression. The company sells these therapy systems, recurring treatment sessions, warranties, and practice management tools to healthcare providers, primarily targeting psychiatrists along with primary care physicians and pain management specialists. Additionally, through its subsidiary Greenbrook, it operates mental health centers that deliver TMS procedures and SPRAVATO nasal spray treatments.
Company profile, executives and historyNeuronetics stock: common questions
What is Neuronetics's stock price?
STIM closed at $1.39 on Nov 13, 2026, down 2.80% on the day. Over the past 52 weeks it traded between $0.80 and $3.44.
What is Neuronetics's market cap?
Neuronetics was worth $105.91M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is STIM's P/E ratio?
Neuronetics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.33), so it has no meaningful P/E ratio.
How much revenue does Neuronetics make?
Neuronetics reported revenue of $159.76M for the twelve months to Sep 30, 2026, up 23.0% from a year earlier.
Does Neuronetics pay a dividend?
No. Neuronetics has not paid a cash dividend over the last twelve months.
When does Neuronetics report earnings next?
Neuronetics is expected to report Q4 FY2026 results on Mar 16, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has STIM stock performed over the past year?
Including dividends, STIM returned -31.9% over the past year, against +13.5% for the S&P 500.
How many STIM shares are sold short?
7M shares were sold short at the latest FINRA report, 17.95% of the float, or 9.9 days of average trading volume.
Who are Neuronetics's competitors?
Companies most similar to Neuronetics by business, industry and size include BWAY, NPCE, ANIK, INFU, TCMD.
See a number that looks wrong?